Wow.
Do you feel we need to worry about the vendors most of us use and we should stock up?
Or is this more about the online stores where you use a credit card?
It could be competitors going after each other, reporting each other to the feds.
I don’t recommend anyone use gray market peptides, much less stock up on them, but there does seem to be this feeling that there’s some kind of a big crackdown coming which has clearly spooked a lot of vendors.
1 Like
I definitely get that. When I recently met with my doc, he said you should be on glp1s for your brain, but pleeeease let me give them to you. They have come down in price and are now ONLY $400 a month.
From https://x.com/PeptideList/status/2030076268788826443
Looks like the collapse of GLP1 sales lead to them closing up.
In December 2025, the site generated $7.45 million in online sales with a 3.0-3.5% conversion rate across 1.15 million sessions. Even accounting for seasonal variation, those numbers suggest annual revenue well into nine figures over the company’s lifetime.
In December 2025, the site generated $7.45 million in online sales with a 3.0-3.5% conversion rate across 1.15 million sessions. Even accounting for seasonal variation, those numbers suggest annual revenue well into nine figures over the company’s lifetime.
To understand the revenue impact, consider that Hims & Hers Health, a single telehealth company operating in the regulated market, earned $225 million from compounded semaglutideduring the shortage period. The gray market GLP-1 segment across all vendors was likely worth multiples of that. When you cut that revenue stream off overnight, the math on continuing operations changes dramatically
For Peptide Sciences, this wasn’t a compliance adjustment. It was an amputation of their most profitable product lines
And like all single vial sellers, they had quality issues and inherent limitations that made quality control almost impossible.
1 Like
Here is a good writeup on the issues, which are industry wide:
The Squeeze That Made Walking Away the Smart Play
Peptide Sciences didn’t wake up on March 6th and decide to close on a whim. The walls had been closing in for months, and the company appeared to be systematically winding down its highest-risk product lines before pulling the plug entirely.
The GLP-1 Cash Cow Dies
The biggest revenue driver in the research peptide market from 2023 through early 2026 wasn’t BPC-157 or TB-500. It was GLP-1 agonists: semaglutide, tirzepatide, and the next-generation triple agonist retatrutide. When brand-name Ozempic and Mounjaro cost $900 to $1,300 per month without insurance, research peptide vendors offered the same molecules for $150 to $300. The economics were irresistible, and the customer base exploded.
Then the FDA started swinging.
In September 2025, the agency issued more than 50 warning letters to companies compounding or manufacturing GLP-1 drugs. These weren’t just aimed at pharmacies. The letters targeted false or misleading statements on websites and promotional materials, specifically claims that products were “generic versions” or contained the “same active ingredient” as FDA-approved drugs.
The SAFE Drugs Act (Safeguarding Americans from Fraudulent and Experimental Drugs Act), introduced in early 2026, went further still, prohibiting the sale of research chemicals biologically identical to FDA-approved drugs without a New Drug Application. Almost overnight, vendors across the industry began scrubbing their catalogs. Semaglutide, tirzepatide, and retatrutide vanished from websites that had been selling them openly for years.
Peptide Sciences had already started pulling GLP-1s before the full shutdown. Their statement at the time: “We have discontinued several items, including Semaglutide, Tirzepatide, Retatrutide, and MK-677, as part of our routine compliance updates and alignment with evolving industry compliance guidance.” The word “routine” was doing a lot of heavy lifting in that sentence.
To understand the revenue impact, consider that Hims & Hers Health, a single telehealth company operating in the regulated market, earned $225 million from compounded semaglutide
during the shortage period. The gray market GLP-1 segment across all vendors was likely worth multiples of that. When you cut that revenue stream off overnight, the math on continuing operations changes dramatically.For Peptide Sciences, this wasn’t a compliance adjustment. It was an amputation of their most profitable product lines.
The domino effect: each FDA enforcement action made the next one more likely.
The 2023 Warning Letter
Peptide Sciences didn’t escape FDA attention entirely. In 2023, the agency issued a warning letter to the company for making health claims about BPC-157 and TB-500 on their website. References to “healing” and “recovery” crossed the line from research chemical sales into drug marketing. The company restructured their website and marketing materials to comply.
This is significant because it establishes direct FDA contact with Peptide Sciences. The agency knew who they were. They were on the radar. Every subsequent enforcement escalation, from the 50+ GLP-1 warning letters to the Amino Asylum raid, would have landed differently when you already had a letter in your file.
The Quality Problem
Here’s a detail the peptide community doesn’t love discussing: independent testing repeatedly flagged quality concerns with Peptide Sciences’ products. Finnrick Analytics, a third-party testing platform that has become the de facto quality watchdog for the research peptide market, gave Peptide Sciences’ retatrutide a rating of E (Bad) based on 34 independent laboratory samples. Their latest test, dated August 4, 2025, confirmed the poor rating.
The problems weren’t subtle. Finnrick found quantities diverging by up to 50% from advertised amounts. In at least one February 2025 test, a compound was incorrectly identified as retatrutide entirely. For context, Finnrick rates vendors on an A-through-E scale across 136 vendors and 1,941 independent tests. An E rating means consistent quality failures across multiple samples. For a company that built its entire brand on scientific credibility and institutional-grade quality, this was devastating.
One X user, Tom Howard, put it bluntly: “How did I know Peptide Sciences sold me fake Retatrutide? I was shown pre-release data from Finnrick.”
When your flagship product category (GLP-1s) is getting legislated out of existence, the FDA already has your name in their files, and your product quality is getting exposed by independent testing, the calculus changes fast.
The Enforcement Escalation
The 12 months before Peptide Sciences shut down saw the most aggressive regulatory enforcement campaign the research peptide market has ever experienced:
December 2024: FDA issues warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs.
June 2025: FDA raids Amino Asylum’s warehouse . Website goes offline. Payment processing terminated. Pending orders frozen. As of March 2026, the site remains dark.
September 2025: FDA issues 50+ warning letters to GLP-1 compounders and manufacturers, with confirmed DOJ involvement. The Center for Drug Evaluation and Research (CDER) warning letters jumped 50% in fiscal year 2025
December 2025: Pinnacle Professional Research (dba Pinnacle Peptides) receives an FDA warning letter for marketing SARMs.
Early 2026: New legislation prohibits selling research chemicals identical to FDA-approved drugs without an NDA. Vendors begin mass catalog purges.
March 6, 2026: Peptide Sciences posts three sentences and goes dark.
The scale of the problem the FDA was responding to is staggering. LegitScript, a compliance monitoring firm used by major payment processors, reported
. E-commerce peptide products grew 276% over five years. The gray market wasn’t shrinking. It was exploding. And that explosion is what made the crackdown inevitable.
The pattern is unmistakable. The FDA moved from warning letters to warehouse raids to legislative ammunition. Each escalation raised the stakes. Each enforcement action made the next one more likely. Peptide Sciences saw the trajectory and made a calculation that every sophisticated business operator would understand: the expected value of continuing operations had turned negative.
The broader point Huberman keeps making is worth sitting with: the FDA isn’t killing peptides. They’re killing the gray market distribution channel. The molecules aren’t going away. The unregulated vendors selling them without oversight, quality control, or accountability are.
Full article here: https://x.com/PeptideList/status/2030076268788826443
This is still in committee in both the House and Senate, so it’s nowhere near being passed or signed into law, thus it doesn’t make sense to me why it would scare vendors until/unless it eventually becomes law. If anything, it seems like vendors would want to keep selling as much as they can, while they still can.
My guess is that the vendors who are closing shop are the ones who haven’t been strictly following the rules and know they’re at risk of prosecution. For instance, if their web site says “research use only” but they have social media posts or emails demonstrating clear awareness that their products are actually being used by everyday human non-researchers.